Compare Cintas Corporation (CTAS) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Hims and Hers Health Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while Hims and Hers Health Inc trades at $28.42 (market cap $6.55B). The key difference: Cintas Corporation is far larger — about 12.2× Hims and Hers Health Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Hims and Hers Health Inc for 21 Days on average.
| CTAS | HIMS | |
|---|---|---|
Market Cap | $79.86B | $6.55B |
Volume | 1,323,583 | 14,842,814 |
Sector | Industrials | Health |
52-Week High | $216.53 | $62.76 |
52-Week Low | $163.55 | $14.52 |
Typical Hold Time | 124 Days | 21 Days |
Enterprise Value | $82.33B | $7.25B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.
The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
